Endothelial cells lining blood vessels regulate vascular barrier function, which controls the passage of plasma proteins and circulating cells across the endothelium. In most normal adult tissues, endothelial cells preserve basal vascular permeability at a low level, while they increase permeability in response to inflammation. Therefore, vascular permeability is tightly controlled by a number of extracellular stimuli and mediators to maintain tissue homeostasis. Accordingly, impaired regulation of endothelial permeability causes various diseases, including chronic inflammation, asthma, edema, sepsis, acute respiratory distress syndrome, anaphylaxis, tumor angiogenesis, and diabetic retinopathy. Vascular endothelial (VE)-cadherin, a member of the classical cadherin superfamily, is a component of cell-to-cell adherens junctions in endothelial cells and plays an important role in regulating vascular permeability. VEcadherin mediates intercellular adhesion through trans-interactions formed by its extracellular domain, while its cytoplasmic domain is anchored to the actin cytoskeleton via α-and β-catenins, leading to stabilization of VE-cadherin at cell-cell junctions. VE-cadherin-mediated cell adhesions are dynamically, but tightly, controlled by mechanisms that involve protein phosphorylation and reorganization of the actomyosin cytoskeleton. Phosphorylation of VE-cadherin, and its associated-catenins, results in dissociation of the VE-cadherin/catenin complex and internalization of VE-cadherin, leading to increased vascular permeability. Furthermore, reorganization of the actomyosin cytoskeleton by Rap1, a small GTPase that belongs to the Ras subfamily, and Rho family small GTPases, regulates VE-cadherinmediated cell adhesions to control vascular permeability. In this review, we describe recent progress in understanding the signaling mechanisms that enable dynamic regulation of VE-cadherin adhesions and vascular permeability. In addition, we discuss the possibility of novel therapeutic approaches targeting the signaling pathways controlling VE-cadherin-mediated cell adhesion in diseases associated with vascular hyper-permeability. (J Nippon Med Sch 2017; 84: 148 159) 
Introduction
Endothelial cells lining the interior surfaces of blood vessels function as a semipermeable barrier to regulate the vascular permeability that is implicated in tissue fluid homeostasis, extravasation of circulating cells, and supplying essential nutrients. Vascular permeability is dynamically, but tightly, controlled by a number of extracellular stimuli and mediators to maintain vascular homeostasis ( Fig. 1) . Thus, endothelial barrier function impairment causes vascular hyper-permeability, promoting the development and progression of various diseases, such as chronic inflammation, asthma, edema, sepsis, acute respiratory distress syndrome, anaphylaxis, tumor angiogenesis, diabetic retinopathy 1,2 ( Fig. 1) . When inflamma- Fig. 1 Dynamic regulation of vascular permeability Endothelial permeability is dynamically, but tightly, controlled by a number of mediators that increase (blue) or decrease (red) endothelial barrier function. In normal adult tissues, endothelial cells preserve basal vascular permeability at a low level (left). When inflammation is induced, inflammatory mediators increase vascular permeability to induce plasma leakage and leukocyte extravasation. Dysregulation of endothelial permeability facilitates the development and progression of various diseases that are associated with vascular hyper-permeability. cytokines increase vascular permeability by inducing intercellular gap formation 2 6 . Vascular endothelial growth factor (VEGF), which is one of the most potent angiogenic factors, also induces vascular permeability 7, 8 . Indeed, VEGF was originally described as a vascular permeability factor 9 . On the other hand, various mediators such as angiopoietin-1 (Ang1) and sphingosine-1-phosphate (S1P) suppress vascular permeability, thereby improving endothelial barrier functions 10, 11 . In addition, production of intracellular cyclic AMP (cAMP), a second messenger downstream from Gs-coupled G proteincoupled receptors (GPCRs), has been shown to reduce vascular permeability 12 14 . Consistently, cAMP-elevating GPCR agonists such as adrenomedullin, prostacyclin (PGI2), prostaglandin E2 (PGE2), and β-adrenergic agonists limit hyper-permeability induced by these inflammatory mediators 15 17 .
Permeability across the endothelium is mediated by transcellular and paracellular pathways: the former involves caveolae-mediated transcytosis of soluble macromolecules, whereas the latter relies on the opening and closing of endothelial cell-cell junctions 18 . 6, 19, 22, 23 .
In this review, we will focus on the regulation of vas- Fig. 2 Schematic representation of VE-cadherin-mediated endothelial cell junctions VE-cadherin is composed of five extracellular cadherin domains, a transmembrane domain, and a highly conserved cytoplasmic tail, and mediates calcium-dependent intercellular adhesions of endothelial cells through cis-and trans-dimerization. The cytoplasmic tail of VE-cadherin binds to p120-catenin and β-catenin. β-catenin further interacts with α-catenin, which, directly or indirectly, links to the actin cytoskeleton. p120: p120-catenin, α: α-catenin, β: β-catenin.
cular permeability by VE-cadherin-mediated endothelial cell-cell junctions and describe recent progress in understanding the signaling mechanisms that enable VEcadherin adhesions and vascular permeability to be dynamically regulated. In the first part of this review, we will highlight the significance of VE-cadherin phosphorylation in the regulation of vascular permeability and leukocyte extravasation. In the latter part, we will introduce the regulatory mechanisms of VE-cadherinmediated cell adhesions through reorganization of the actomyosin cytoskeleton, focusing especially on Rap1 and Rho-family small GTPases.
Molecular Organization of VE-cadherin-based AJs
VE-cadherin, also known as cadherin-5 and CD144, belongs to the classical cadherin superfamily 6, 19 . It is composed of five extracellular cadherin domains, a transmembrane domain and a highly conserved cytoplasmic tail, and mediates calcium-dependent intercellular adhesions by initially forming cis-dimers at the cell surface via its extracellular cadherin domains followed by an antiparallel trans-interaction of dimers on opposing cells (Fig. 2) . 29 31 .
Regulation of Vascular Permeability through
Phosphorylation of VE-cadherin and Its Associated Catenins Permeability-increasing agents such as VEGF, histamine, bradykinin, tumor necrosis factor, PAF, and thrombin induce phosphorylation of the VE-cadherin cytoplasmic tail and of its associated catenins, in turn leading to increased vascular permeability via VE-cadherin/catenin dissociation and VE-cadherin internalization 6, 32, 33 . The phosphorylation of VE-cadherin is also induced by leukocyte adhesion to endothelial cells through intercellular cell adhesion molecule-1 (ICAM-1) and is involved in diapedesis of leukocytes 3, 33 .
VEGF induces vascular permeability through activation of non-receptor tyrosine kinase Src 23, 34, 35 (Fig. 3) . Stimulation with VEGF induces phosphorylation of several tyrosine residues of its receptor, VEGF receptor-2 (VEGFR2) 36 .
T cell-specific adaptor (TSAd) binds to phospho-Y951 within VEGFR2 and subsequently recruits and activates Src, which directly phosphorylates VE-cadherin to increase vascular permeability 37, 38 . In addition, Src reportedly induces activation of p21-activated kinase, which in turn phosphorylates the VE-cadherin on serine residues, leading to its internalization and weakening of cell-cell junctions 39 . In addition to Src, focal adhesion kinase (FAK) is activated by VEGF and promotes vascular permeability by inducing phosphorylation of β-catenin and its subsequent dissociation from VE-cadherin 40 ( Fig. 3) .
The specific tyrosine residues of VE-cadherin that are 47, 51 . The Small GTPase Rap1 is a Key Regulator of VE-cadherin-mediated Cell-cell Adhesions cAMP is a well-known intracellular signaling molecule that improves endothelial barrier functions 12 14 . Previously, we, and others, investigated the molecular mechanism underlying cAMP-induced endothelial barrier enhancement and identified Rap1 as a key downstream molecule of cAMP for potentiating VE-cadherin-mediated cell adhesions 58, 61, 62 . Rap1 is a small GTPase that belongs to the Ras subfamily and was originally identified as an antagonist of Ras-induced transformation 63, 64 . In addition, Rap1
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is known to promote cell-extracellular matrix (ECM) adhesions by stimulating integrin activity 63, 65 . Rap1 becomes the GTP-bound active form via several guanine nucleotide exchange factors (GEFs), among which, exchange protein directly activated by cAMP (Epac) is a cAMPresponsive GEF for Rap1 66 . Thus, cAMP potentiates VEcadherin-mediated cell-cell contacts to enhance endothelial barrier function through an Epac-Rap1 signaling pathway 58, 61, 62 . In addition, it has been shown that VEcadherin engagement leads to Rap1 activation at nascent cell-cell contacts through PDZ-GEF, another GEF for Rap1, which in turn facilitates maturation of VEcadherin-based AJs 67, 68 . Similarly, Rap1 is involved in the formation and stabilization of E-cadherin-based cell-cell adhesions in epithelial cells 69 71 . Thus, Rap1 has recently been recognized as a key mediator not only for integrinmediated cell-ECM adhesions but also for cadherin-based cell-cell adhesions. (Fig. 4) .
Molecular Mechanism Underlying Rap1-induced Endothelial Barrier Enhancement

Rap1-induced activation of junctional NM-II, through
the Cdc42-MRCK pathway, generates tension on the (Fig. 4) . However, since Rac also negatively regulates endothelial barrier functions 39, 88, 89 , the role (Fig. 5) .
Therefore, impaired regulation of this balance might promote the development and progression of various disease states that are associated with hyper-permeability, such as chronic inflammation, asthma, edema, sepsis, acute respiratory distress syndrome, anaphylaxis, tumor angiogenesis, diabetic retinopathy (Fig. 5) . Thus, normalizing the balance between the Rho signaling involved in focal AJ formation and the Cdc42/Rac signaling involved in linear AJ formation could represent an effective therapeutic intervention for these diseases (Fig. 5) . Indeed, ad- . Importantly, they further revealed that ABTAA is highly effective in augmenting survival from sepsis, at least in part, by reducing vascular leakage.
Conclusions and Future Perspectives
In this review, we have summarized recent progress in unraveling the molecular mechanisms underlying the dy- 
